Jesus Garcia-Foncillas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jesus Garcia-Foncillas has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Eva Bandrés
Immunology Unit, Hematology Department Hospital Universitario de Navarra Pamplona Spain
4 shared publications - Ruth Zarate
Laboratory of Pharmacogenomics, Division of Oncology, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona-Navarra 31008, Spain
2 shared publications A Viudez
Unit for the Research and Treatment of Gastrointestinal Malignancies, Department of Oncology Pamplona, Spain
1 shared publication- Ana Chopitea
Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain
1 shared publication - Ana Patiño-García
Departamento de Pediatría y Cancer Center Clínica Universidad de Navarra (CUN), Unidad de Medicina Genómica, Laboratorio de Terapias Avanzadas para Tumores Sólidos Pediátricos, Programa de Tumores Sólidos, CIMA Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain
1 shared publication - Carlos Panizo
Hematology Laboratory Donostia University Hospital Donostia‐San Sebastian Spain
1 shared publication
Latest Publications
- Open Access
- 16 January 2012
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 13 (1) , 840-865
MiRNAs and LincRNAs: Could They Be Considered as Biomarkers in Colorectal Cancer?
Recent advances in the field of RNA research have provided compelling evidence implicating microRNA (miRNA) and long non-coding RNA molecules in many diverse and substantial biological processes, including transcriptional and post-transcriptional regulation of gene expression, genomic imprinting, and modulation of protein activity. Thus, studies of non-coding RNA (ncRNA) may contribute to the discovery of possible biomarkers in human cancers. Considering that the response to chemotherapy can differ amongst individuals, researchers have begun to isolate and identify the genes responsible. Identification of targets of this ncRNA associated with cancer can suggest that networks of these linked to oncogenes or tumor suppressors play pivotal roles in cancer development. Moreover, these ncRNA are attractive drug targets since they may be differentially expressed in malignant versus normal cells and regulate expression of critical proteins in the cell. This review focuses on ncRNAs that are differently expressed in malignant tissue, and discusses some of challenges derived from their use as potential biomarkers of tumor properties.
- 16 January 2012
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 13 (1) , 840-865
Open AccessMiRNAs and LincRNAs: Could They Be Considered as Biomarkers in Colorectal Cancer?
Recent advances in the field of RNA research have provided compelling evidence implicating microRNA (miRNA) and long non-coding RNA molecules in many diverse and substantial biological processes, including transcriptional and post-transcriptional regulation of gene expression, genomic imprinting, and modulation of protein activity. Thus, studies of non-coding RNA (ncRNA) may contribute to the discovery of possible biomarkers in human cancers. Considering that the response to chemotherapy can differ amongst individuals, researchers have begun to isolate and identify the genes responsible. Identification of targets of this ncRNA associated with cancer can suggest that networks of these linked to oncogenes or tumor suppressors play pivotal roles in cancer development. Moreover, these ncRNA are attractive drug targets since they may be differentially expressed in malignant versus normal cells and regulate expression of critical proteins in the cell. This review focuses on ncRNAs that are differently expressed in malignant tissue, and discusses some of challenges derived from their use as potential biomarkers of tumor properties.
- Open Access
- 29 June 2010
- Published by Springer Nature in The Pharmacogenomics Journal
- Vol. 11 (6) , 429-436
Role of primary miRNA polymorphic variants in metastatic colon cancer patients treated with 5-fluorouracil and irinotecan
MicroRNAs are non-coding RNAs that can block mRNA translation and influence mRNA stability. Recent evidence indicates that miRNA variations can affect drug resistance, efficacy, and metabolism, opening new avenues of pharmacogenomics research. We investigated associations between polymorphisms in both miRNA-containing genomic regions (primary and precursor miRNA) and in genes related to miRNA biogenesis with clinical outcome in metastatic colorectal cancer (mCRC) patients treated with 5-fluorouracil and irinotecan (CPT-11). Eighteen single-nucleotide polymorphisms (SNPs) were analyzed in 61 patients. A significant association with tumor response and time to progression (TTP) was found for SNP rs7372209 in pri-miR26a-1 (P=0.041 and P=0.017, respectively). The genotypes CC and CT were favorable when compared with the TT variant genotype. In addition, SNP rs1834306, located in the pri-miR-100 gene, significantly correlated with a longer TTP (P=0.04). In the miRNA-biogenesis pathway, a trend was identified between SNP rs11077 in the exportin-5 gene and disease control rate (P=0.076). This study is the first to suggest a relationship between treatment outcome and SNPs in the miRNA-biogenesis machinery, in both primary and precursor miRNAs. Our results suggest that miRNA polymorphic variants might be useful predictors of clinical outcome in mCRC patients treated with 5-fluorouracil and CPT-11 combination.
- 29 June 2010
- Published by Springer Nature in The Pharmacogenomics Journal
- Vol. 11 (6) , 429-436
Open AccessRole of primary miRNA polymorphic variants in metastatic colon cancer patients treated with 5-fluorouracil and irinotecan
MicroRNAs are non-coding RNAs that can block mRNA translation and influence mRNA stability. Recent evidence indicates that miRNA variations can affect drug resistance, efficacy, and metabolism, opening new avenues of pharmacogenomics research. We investigated associations between polymorphisms in both miRNA-containing genomic regions (primary and precursor miRNA) and in genes related to miRNA biogenesis with clinical outcome in metastatic colorectal cancer (mCRC) patients treated with 5-fluorouracil and irinotecan (CPT-11). Eighteen single-nucleotide polymorphisms (SNPs) were analyzed in 61 patients. A significant association with tumor response and time to progression (TTP) was found for SNP rs7372209 in pri-miR26a-1 (P=0.041 and P=0.017, respectively). The genotypes CC and CT were favorable when compared with the TT variant genotype. In addition, SNP rs1834306, located in the pri-miR-100 gene, significantly correlated with a longer TTP (P=0.04). In the miRNA-biogenesis pathway, a trend was identified between SNP rs11077 in the exportin-5 gene and disease control rate (P=0.076). This study is the first to suggest a relationship between treatment outcome and SNPs in the miRNA-biogenesis machinery, in both primary and precursor miRNAs. Our results suggest that miRNA polymorphic variants might be useful predictors of clinical outcome in mCRC patients treated with 5-fluorouracil and CPT-11 combination.
- Open Access
- 9 March 2010
- Published by Springer Nature in British Journal of Cancer
- Vol. 102 (6) , 987-994
Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis
Background: Methods: Results: Conclusion:
- 9 March 2010
- Published by Springer Nature in British Journal of Cancer
- Vol. 102 (6) , 987-994
Open AccessOxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis
Background: Methods: Results: Conclusion:
- Open Access
- 1 January 2009
- Published by Springer Nature in Cases Journal
- Vol. 2, 6384
Primary bone lymphoma of the mandible and thyroid incidentaloma identified by 18FDG PET/CT: a case report
The mandible is a rare site for the occurrence of primary bone lymphoma (PBL), a non-Hodgkin lymphoma. We report herein a case of an incidentally diagnosed thyroid incidentaloma by (18)Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in a patient with a previous diagnosis of PBL. Therapeutic options are reviewed and discussed.
- 1 January 2009
- Published by Springer Nature in Cases Journal
- Vol. 2, 6384
Open AccessPrimary bone lymphoma of the mandible and thyroid incidentaloma identified by 18FDG PET/CT: a case report
The mandible is a rare site for the occurrence of primary bone lymphoma (PBL), a non-Hodgkin lymphoma. We report herein a case of an incidentally diagnosed thyroid incidentaloma by (18)Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in a patient with a previous diagnosis of PBL. Therapeutic options are reviewed and discussed.
- 1 April 2006
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 8 (4) , 250-261
Proteomic analysis in cancer research: potential application in clinical use
- 1 April 2006
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 8 (4) , 250-261
Proteomic analysis in cancer research: potential application in clinical use